Clinical Data announces 2006 launch of genetic test for warfarin response

By Elaine Rigoli

Tampa, Fla., June 6 - Clinical Data, Inc. announced that its PGxHealth division will provide a genetic test to clinicians that is associated with response to warfarin, a commonly prescribed drug to treat and prevent blood clots associated with stroke, heart attack and other clotting disorders.

Clinical Data said this test is a direct result of its intellectual property licenses under which the company has been granted commercialization rights relating to certain polymorphisms in the Vitamin K epoxide reductase complex gene (Vkor1).

Polymorphisms within the Vkor1 gene are one of the important predictors of response to warfarin, according to a news release.

Clinical Data noted that assessment of warfarin metabolism based on certain polymorphisms in the well-known Cyp2c9 gene accounts for about 17% of the variability in warfarin dosing while analysis of the Vkor1 gene polymorphisms accounts for an additional 15% of the variability.

Newton, Mass.-based Clinical Data provides molecular and pharmacogenomics services as well as genetic tests.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.